Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Share-based Compensation (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Share-based Compensation for 17 consecutive years, with $2.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation fell 74.31% to $2.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $35.2 million, a 29.32% decrease, with the full-year FY2025 number at $35.2 million, down 29.32% from a year prior.
  • Share-based Compensation was $2.8 million for Q4 2025 at Myriad Genetics, down from $12.2 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $14.5 million in Q2 2024 to a low of $2.8 million in Q4 2025.
  • A 5-year average of $10.0 million and a median of $10.2 million in 2022 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: skyrocketed 60.0% in 2024, then tumbled 74.31% in 2025.
  • Myriad Genetics' Share-based Compensation stood at $8.4 million in 2021, then decreased by 2.38% to $8.2 million in 2022, then grew by 26.83% to $10.4 million in 2023, then increased by 4.81% to $10.9 million in 2024, then crashed by 74.31% to $2.8 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Share-based Compensation are $2.8 million (Q4 2025), $12.2 million (Q3 2025), and $10.7 million (Q2 2025).